Navigation Links
As Billions in Blockbuster Drug Revenue Goes Off Patent, Life Sciences Companies are Challenged to Fundamentally Change Future R&D Strategies, According to New Deloitte Report
Date:4/2/2008

NEW YORK, April 2, 2008 /PRNewswire-USNewswire/ -- Pharmaceutical companies currently challenged with replacing the $65 billion worth of product expected to go off patent in the next four years must dramatically rethink their R&D models for future success, according to a new report released by Deloitte today.

According to the report titled The Changing Face of R&D in the Future Pharmaceutical Landscape (http://www.deloitte.com/us/FuturePharma), current R&D programs focused on developing a small portfolio of high revenue blockbusters will evolve to R&D programs focused on high efficacy treatments developed for smaller patient populations based on specific genotypes. Such treatments, and their higher demonstrated efficacy, may ultimately have the potential for higher per treatment revenues.

This fundamental disruption of today's pharmaceutical industry will create both opportunities and threats for current industry players, and will stimulate the emergence of new industry entrants configured specifically to succeed in the changed pharmaceutical landscape.

"Continuing yesterday's R&D focus on developing blockbusters will not secure success in the future," according to Terri Cooper, Ph.D., a principal in the Life Sciences practice of Deloitte Consulting LLP. "Pharmaceutical companies cannot rest on their laurels. They need to be looking outside of their four walls to develop partnerships and collaborations with a network of companies, scientists and organizations to fuel R&D developments and reduce time to bring new drugs to market."

The R&D model of the future will incorporate:

-- R&D strategies which support the assembly of treatment portfolios for the entire disease life cycle and the various genotype specific patient segments in the life cycle, rather than the traditional one-off "blockbuster"

-- Focused R&D programs based on genotyped patients/subjects and biomarkers

-- Virtual, disease-specific R&D networks, incorporating patients, physicians and the medical treatment infrastructure, which involves extensive partnering and collaboration with all the disease knowledge communities

-- Virtual R&D processes with significant outsourcing to maximize flexibility and manage development risk

"Leading pharmaceutical companies who follow this new R&D approach will be well positioned to reap the benefits of future R&D investments building the development pipelines required to compete in the next five years," said Dr. Cooper.

Additionally, the rise of consumerism in the health care industry further supports the urgency for change as blockbuster drugs go off patent and compete with generics. A recent Deloitte Center for Health Solutions report, 2008 Survey of Health Care Consumers (http://www.deloitte.com/us/consumerism), found that 84 percent of consumers surveyed prefer generic drugs to name brand drugs if given the choice.

"R&D investments must now more than ever be geared at developing the types of compounds that will have even greater safety and efficacy to establish branded drugs as preferred choices to contend with increasing generic competition," added Dr. Cooper.

Related Content:

Full Report: The Changing Face of R&D in the Future Pharmaceutical Landscape - http://www.deloitte.com/us/FuturePharma

Survey: 2008 Survey of Health Care Consumers - http://www.deloitte.com/us/consumerism

About Deloitte

As used in this document, "Deloitte" means Deloitte LLP. Please see http://www.deloitte.com/about for a detailed description of the legal structure of Deloitte LLP and its subsidiaries.

CONTACT:

Marykate Reese

Public Relations

Deloitte

+1 203 257 0452

mareese@deloitte.com

Dana Christiansen

Senior Account Executive

Hill & Knowlton

+1 212 885 0359

dana.christiansen@hillandknowlton.com


'/>"/>
SOURCE Deloitte
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Biogenerics Will Save Billions, Says Hospira CEO
2. So Long, Old Friend: The End of the Blockbuster Drug Era? What 2008 Holds for Bringing Drugs to Market
3. Merck Will Obtain Blockbuster Antidiabetic Drug Sales in Type 2 Diabetes Market by 2011
4. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
5. Plethora and Paul Capital Healthcare sign a $25 million revenue interest financing agreement with an option for an additional $3 million equity investment
6. Kiwa Bio-Tech Year-End Revenues Increase 264% - Exceed $9.1 Million
7. Neogen Reports 34% Increase in Net Income, 20% Increase in Revenues
8. Profarmas Gross Revenue Reached R$ 740,4 Million in the 4th Quarter of 2007, a 40,1% Growth Over the Same Period in the Last Year
9. Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36%
10. Phlo Reports Sharp Revenue Increase
11. Osteotech Reports 2007 Full Year and Fourth Quarter Financial Results; Full Year Revenue of $104.3 Million Exceeds $100 Million Milestone; Diluted Earnings Per Share Was $.15 in 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... , ... STACS DNA Inc., the sample tracking software company, today announced that ... joined STACS DNA as a Field Application Specialist. , “I am thrilled that ... of STACS DNA. “In further expanding our capacity as a scientific integrator, Hays brings ...
(Date:6/23/2016)... 23, 2016  Blueprint Bio, a company dedicated to ... medical community, has closed its Series A funding round, ... "We have received a commitment from Forentis ... need to meet our current goals," stated Matthew ... runway to complete validation on the current projects in ...
(Date:6/23/2016)... CA (PRWEB) , ... June 23, 2016 , ... ... software, is exhibiting at the Pennsylvania Convention Center and will showcase its product’s ... conference. ClinCapture will also be presenting a scientific poster on Disrupting Clinical Trials ...
(Date:6/23/2016)...  Amgen (NASDAQ: AMGN ) today announced ... life sciences incubator to accelerate the development of new ... at QB3@953 was created to help high-potential life science ... early stage organizations - access to laboratory infrastructure. ... two "Amgen Golden Ticket" awards, providing each winner with ...
Breaking Biology Technology:
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a ... the MegaMatcher Automated Biometric Identification System (ABIS) ... large-scale multi-biometric projects. MegaMatcher ABIS can process multiple ... using any combination of fingerprint, face or iris ... MegaMatcher SDK and MegaMatcher Accelerator , ...
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
(Date:4/26/2016)... Research and Markets has announced ... 2016-2020"  report to their offering.  , ,     (Logo: ... analysts forecast the global multimodal biometrics market to ... period 2016-2020.  Multimodal biometrics is being ... the healthcare, BFSI, transportation, automotive, and government for ...
Breaking Biology News(10 mins):